Stay updated on TILs Plus IL-2 Versus Pembrolizumab in Melanoma Clinical Trial

Sign up to get notified when there's something new on the TILs Plus IL-2 Versus Pembrolizumab in Melanoma Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the TILs Plus IL-2 Versus Pembrolizumab in Melanoma Clinical Trial page

  1. Check
    7 days ago
    Change Detected
    Summary
    Added 'Melanoma' as a related topic and included 'MedlinePlus Genetics' as related topics, expanding cross-referencing and searchability for the page. The page revision was updated to v3.5.4, indicating a minor metadata update.
    Difference
    0.2%
    Check dated 2026-05-15T15:24:43.000Z thumbnail image
  2. Check
    14 days ago
    Change Detected
    Summary
    The page’s related topics section now lists Melanoma and MedlinePlus Genetics. These additions broaden navigational links to melanoma-related information and genetics resources on the page.
    Difference
    0.1%
    Check dated 2026-05-08T11:55:30.000Z thumbnail image
  3. Check
    21 days ago
    Change Detected
    Summary
    The follow-up visit cadence for participants is now specified: 2-day follow-up visits occur every 1-3 months for the first year, then every 6 months. This clarifies the post-treatment monitoring timeline within the Study Plan.
    Difference
    0.2%
    Check dated 2026-05-01T09:23:36.000Z thumbnail image
  4. Check
    28 days ago
    Change Detected
    Summary
    The page’s update/history entries were refreshed (including the revision identifier), replacing an older revision entry with a newer one. The follow-up-visit text was adjusted only slightly (ellipsis/punctuation) without changing the described frequency or timing.
    Difference
    0.2%
    Check dated 2026-04-24T06:29:04.000Z thumbnail image
  5. Check
    35 days ago
    Change Detected
    Summary
    Added Revision: v3.5.2. Removed Melanoma and the related topics entry MedlinePlus Genetics, and removed Revision: v3.5.0.
    Difference
    0.2%
    Check dated 2026-04-17T02:44:42.000Z thumbnail image
  6. Check
    50 days ago
    Change Detected
    Summary
    Inclusion criteria were standardized to 18-72 years and clarified lab and cardiac thresholds (ALT/AST ≤ 2.5× ULN; total bilirubin ≤ 1.5 mg/dL with Gilbert's syndrome exception; LVEF ≤ 45% for select patients).
    Difference
    0.5%
    Check dated 2026-04-02T15:34:26.000Z thumbnail image

Stay in the know with updates to TILs Plus IL-2 Versus Pembrolizumab in Melanoma Clinical Trial

Enter your email address, and we'll notify you when there's something new on the TILs Plus IL-2 Versus Pembrolizumab in Melanoma Clinical Trial page.